Download presentation
Presentation is loading. Please wait.
Published byΓερασιμος Μιχαλολιάκος Modified over 6 years ago
1
Metabolically Healthy Patients With Obesity
2
Introduction/Overview
3
Who Are the Patients With MHO?
4
Phenotyping Patients With MHO: Key Clinical Parameters
5
Clinical and Functional Characteristics: MHO vs MUO
6
The Global Epidemic of Obesity
7
Obesity as a Mediator of CVD
8
Patients With MHO: Dueling Data Sets
9
Weight Loss Improves Metabolic Risk Factors in Both Patients With MHO and Patients With MUO
10
Diabetes Prevention Program: Moderate Weight Loss Associated With Reduced Incidence of T2DM
11
Look AHEAD Results: Incidence of Very-High-Risk Chronic Kidney Disease by Treatment Group
12
SCALE Obesity and Prediabetes Trial
13
Orlistat-Induced Weight Loss and Maintenance at 1 Year
14
Weight Loss From Baseline for the Modified-ITT-LOCF Population and the Completer Population: Naltrexone + Bupropion vs Placebo
15
SCALE: Change in Body Weight (%), Liraglutide vs Placebo
16
SCALE Maintenance: Patients Maintaining Run-In Weight Loss or Regaining ≥ 5%
17
Summary and Conclusions
18
Abbreviations
19
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.